{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:01:06Z","timestamp":1762347666419,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"am","delay-in-days":709,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFF0723400"],"award-info":[{"award-number":["2023YFF0723400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2017ZX0931057"],"award-info":[{"award-number":["2017ZX0931057"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bmc.2024.117935","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T22:50:15Z","timestamp":1728082215000},"page":"117935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design, synthesis and biological evaluation of arylpropylamine derivatives as potential multi-target antidepressants"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7662-6319","authenticated-orcid":false,"given":"Quxiang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117935_b0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0140-6736(22)02080-3","article-title":"Novel and emerging treatments for major depression","volume":"401","author":"Marwaha","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2024.117935_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116285","article-title":"Discovery of a novel class of reversible monoacylglycerol lipase inhibitors for potential treatment of depression","volume":"268","author":"Hao","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117935_b0015","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1017\/S0033291709992285","article-title":"Depression and cancer mortality: a meta-analysis","volume":"40","author":"Pinquart","year":"2010","journal-title":"Psychol Med"},{"key":"10.1016\/j.bmc.2024.117935_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.848251","article-title":"Epigenetic mechanism of 5-HT\/NE\/DA triple reuptake inhibitor on adult depression susceptibility in early stress mice","volume":"13","author":"Meng","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2024.117935_b0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852921000791","article-title":"Novel antidepressant drugs: beyond monoamine targets","volume":"28","author":"Gonda","year":"2021","journal-title":"CNS Spectr"},{"key":"10.1016\/j.bmc.2024.117935_b0030","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine(Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117935_b0035","first-page":"420","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"16","author":"Cipriani","year":"2018","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"10.1016\/j.bmc.2024.117935_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116564","article-title":"Synthesis and biological evaluation of multimodal monoaminergic arylpiperazine derivatives with potential antidepressant profile","volume":"275","author":"Zheng","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117935_b0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pharmthera.2006.07.002","article-title":"Differentiating antidepressants of the future: efficacy and safety","volume":"113","author":"Rosenzweig-Lipson","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2024.117935_b0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/0269881116681456","article-title":"Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors","volume":"31","author":"Xue","year":"2017","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.bmc.2024.117935_b0055","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1021\/acs.jmedchem.6b01827","article-title":"Triple reuptake inhibitors as potential therapeutics for depression and other disorders: design paradigm and developmental challenges","volume":"61","author":"Subbaiah","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117935_b0060","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2024.117935_b0065","doi-asserted-by":"crossref","first-page":"13514","DOI":"10.1021\/acs.jmedchem.0c01193","article-title":"Repurposing of DRUGS-THE KETAMINE STORY","volume":"63","author":"Das","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117935_b0070","first-page":"167","article-title":"Treatment-resistant depression","volume":"80","author":"Little","year":"2009","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.bmc.2024.117935_b0075","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2174\/1570159X19666211102154311","article-title":"Design strategies, chemistry and therapeutic insights of multi-target directed ligands as antidepressant agents","volume":"20","author":"Singh","year":"2022","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.bmc.2024.117935_b0080","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.drudis.2020.07.004","article-title":"Recent advances in multi-target directed ligands targeting G-protein-coupled receptors","volume":"25","author":"Ma","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2024.117935_b0085","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1517\/14656566.2012.721776","article-title":"Evidence for the use of vilazodone in the treatment of major depressive disorder","volume":"13","author":"Reinhold","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bmc.2024.117935_b0090","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/NDT.S39544","article-title":"New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder","volume":"10","author":"Katona","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.bmc.2024.117935_b0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0079-6123(08)00914-X","article-title":"Physiological and therapeutic relevance of constitutive activity of 5-HT2A and 5-HT2C receptors for the treatment of depression","volume":"172","author":"Berg","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.bmc.2024.117935_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115028","article-title":"\u201cSelective\u201d serotonin 5-HT2A receptor antagonists","volume":"200","author":"Casey","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2024.117935_b0105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pnpbp.2015.12.006","article-title":"5-HT2C receptors in psychiatric disorders: a review","volume":"66","author":"Chagraoui","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bmc.2024.117935_b0110","doi-asserted-by":"crossref","first-page":"9015","DOI":"10.3390\/ijms22169015","article-title":"5-HT receptors and the development of new antidepressants","volume":"22","author":"\u015alifirski","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117935_b0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/YCO.0b013e32831be9ef","article-title":"Augmentation strategies for treatment-resistant depression","volume":"22","author":"Carvalhoa","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.bmc.2024.117935_b0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2014.07.044","article-title":"Treatment of cognitive dysfunction in major depressive disorder\u2013a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin\u2013norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine","volume":"753","author":"Pehrson","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2024.117935_b0125","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0022-3565(24)37161-7","article-title":"Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites","volume":"283","author":"Owens","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2024.117935_b0130","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(99)11381-3","article-title":"SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression","volume":"355","author":"Kent","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2024.117935_b0135","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1016\/j.bmc.2006.02.029","article-title":"Synthesis and biodistribution of [11C]R107474, a new radiolabeled a2-adrenoceptor antagonist","volume":"14","author":"Mey","year":"2006","journal-title":"Bioorg Med Chem."},{"key":"10.1016\/j.bmc.2024.117935_b0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4088\/JCP.v60n0110","article-title":"Mirtazapine augmentation in the treatment of refractory depression","volume":"60","author":"Carpenter","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.bmc.2024.117935_b0145","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1021\/jm200682b","article-title":"Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT2A receptor and 5-HT transporter","volume":"54","author":"Seo","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117935_b0150","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","article-title":"Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes","volume":"20","author":"Lawler","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bmc.2024.117935_b0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1527-3458.2001.tb00189.x","article-title":"Paroxetine: a review","volume":"7","author":"Bourin","year":"2001","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.bmc.2024.117935_b0160","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1248\/bpb.b13-00645","article-title":"Neuropharmacologic studies on the brain serotonin1A receptor using the selective agonist osemozotan","volume":"36","author":"Matsuda","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.bmc.2024.117935_b0165","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2174\/156802606778249810","article-title":"Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century\u2013a medicinal chemistry survey","volume":"6","author":"Moltzen","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2024.117935_b0170","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1124\/jpet.118.248351","article-title":"Pharmacological characterization of H05, a novel serotonin and noradrenaline reuptake inhibitor with moderate 5-HT2A antagonist activity for the treatment of depressions","volume":"365","author":"Xu","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2024.117935_b0175","first-page":"37","article-title":"Weight gain and antidepressants","volume":"61","author":"Fava","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.bmc.2024.117935_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.704281","article-title":"Antidepressant drugs effects on blood pressure","volume":"8","author":"Calvi","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.bmc.2024.117935_b0185","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1017\/S1092852900017089","article-title":"Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines","volume":"13","author":"Stahl","year":"2008","journal-title":"CNS Spectr"},{"key":"10.1016\/j.bmc.2024.117935_b0190","doi-asserted-by":"crossref","first-page":"727","DOI":"10.5114\/aoms.2019.86928","article-title":"Effects of antidepressants on QT interval in people with mental disorders","volume":"16","author":"Aronow","year":"2020","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.bmc.2024.117935_b0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2165\/00002018-199411010-00003","article-title":"Adverse effects of \u03b11-adrenergic blocking drugs","volume":"11","author":"Carruthers","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.bmc.2024.117935_b0200","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2515\/therapie:2005065","article-title":"Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies","volume":"60","author":"Millan","year":"2005","journal-title":"Therapie"},{"key":"10.1016\/j.bmc.2024.117935_b0205","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21445","article-title":"Development of safe drugs: the hERG challenge","volume":"38","author":"Kalyaanamoorthy","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2024.117935_b0210","unstructured":"Center for drug evaluation and research approval package for: application number 21-427, Pharmacology Review(s) #3, p29-45. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/021427_s000_Cymbalta_Pharmr_P2.pdf."},{"key":"10.1016\/j.bmc.2024.117935_b0215","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","article-title":"The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.bmc.2024.117935_b0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-004-2048-7","article-title":"Forced swimming test in mice: a review of antidepressant activity","volume":"177","author":"Petit-Demouliere","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bmc.2024.117935_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112709","article-title":"Isoquinolinone derivatives as potent CNS multi-receptor D2\/5-HT1A\/5-HT2A\/5-HT6\/5-HT7 agents: Synthesis and pharmacological evaluation","volume":"207","author":"Jin","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117935_b0230","doi-asserted-by":"crossref","unstructured":"Wu J, Li JH, Gaurav C, et al., CUMS and dexamethasone induce depression-like phenotypes in mice by differentially altering gut microbiota and triggering macroglia activation, Gen Psychiatr. 2021;34 (6): 100529, 10.1136\/gpsych-2021-100529.","DOI":"10.1136\/gpsych-2021-100529"},{"key":"10.1016\/j.bmc.2024.117935_b0235","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0091-3057(01)00625-6","article-title":"Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test","volume":"71","author":"Kitamura","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bmc.2024.117935_b0240","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/dta.1333","article-title":"Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model","volume":"4","author":"Canala","year":"2012","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bmc.2024.117935_b0245","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ejmech.2007.10.032","article-title":"Synthesis, spectral studies and antiamoebic activity of new 1-N-substituted thiocarbamoyl-3-phenyl-2-pyrazolines","volume":"44","author":"Abid","year":"2009","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117935_b0250","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1021\/op800289h","article-title":"An investigation on key parameters that influence the synthesis of (S)-(+)-N, N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propylamine: a key intermediate for duloxetine","volume":"13","author":"Suthrapu","year":"2009","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmc.2024.117935_b0255","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1107\/S0108767307043930","article-title":"A short history of SHELX","volume":"64","author":"Sheldrick","year":"2008","journal-title":"Acta Crystallogr A"},{"key":"10.1016\/j.bmc.2024.117935_b0260","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1021\/acs.jmedchem.5b01215","article-title":"Exploring the mechanism of \u03b2-lactam ring protonation in the class A \u03b2-lactamase acylation mechanism using neutron and X-ray crystallography","volume":"59","author":"Vandavasi","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117935_b0265","doi-asserted-by":"crossref","unstructured":"Peng Y, McCorvy JD, Harps\u00f8e K, et al. 5-HT2C receptor structures reveal the structural basis of GPCR polypharmacology, Cell. 72 (4) 719-730, 10.1016\/j.cell.2018.01.001.","DOI":"10.1016\/j.cell.2018.01.001"},{"key":"10.1016\/j.bmc.2024.117935_b0270","doi-asserted-by":"crossref","unstructured":"Coleman JA, Green EM, Gouaux E, X-ray structures and mechanism of the human serotonin transporter, Nature. 532(7599):334-9, 10.1038\/nature17629.","DOI":"10.1038\/nature17629"},{"key":"10.1016\/j.bmc.2024.117935_b0275","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2024.117935_b0280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10822-010-9395-8","article-title":"Computer-aided drug design platform using PyMOL","volume":"25","author":"Lill","year":"2011","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bmc.2024.117935_b0285","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0272-0590(85)90059-4","article-title":"An up-and-down procedure for acute toxicity testing","volume":"5","author":"Bruce","year":"1985","journal-title":"Fundam Appl Toxicol"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624003493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624003493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:56:38Z","timestamp":1762347398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624003493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":57,"alternative-id":["S0968089624003493"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117935","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of arylpropylamine derivatives as potential multi-target antidepressants","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117935"}}